Abstract: A hypodermic needleless injection system for injecting a liquid medication, which system comprises: a medication unit configured and dimensioned to store a volume of liquid to be injected, the medication unit having a first region and a second region that are in liquid communication with each other, the first region being deformable and the second region having at least one orifice, a hydrostatic chamber containing a hydrostatic pressure transfer medium, the hydrostatic chamber being so configured and dimensioned that the medication unit is located at least partially within the hydrostatic chamber and so that a pressure exerted on the transfer medium would cause the first region of the medication unit to deform so as to reduce the volume available for the liquid medication within the medication unit, and a first piston having a first end and a second end opposite to the first end, the first end having a surface which forms a closure of the hydrostatic chamber, and is adapted for applying a pressure on the tra
Type:
Grant
Filed:
February 12, 2001
Date of Patent:
August 27, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Hans-Peter Haar, Hans List, George Bevan Kirby Meacham
Abstract: The present invention provides a pharmaceutical combination preparation comprising an erythropoietin preparation that provides active erythropoietin and at least one modified haemoglobin wherein the erythropoietin preparation and modified haemoglobin can be present in separate forms of administration or in a single form of administration. The pharmaceutical combination preparations of the present invention can be used to treat manifest anemias with or without iron utilization disorders.
Type:
Grant
Filed:
February 7, 2000
Date of Patent:
August 27, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Paul Lehmann, Jürgen Feuerstein, Michael Harold Town
Abstract: The present invention concerns a method for determining and monitoring tissue glucose concentration. Additionally, the present invention concerns a measuring apparatus to determine and monitor glucose concentration.
Abstract: A pill dispenser allows for alternating removal of two or more solid forms of pharmaceutical medications, such as tablets, film tablets, coated tablets, or capsules. The pill dispenser has a housing, a baseplate, at least two storage containers for receiving and storing a solid form of medication, and a dosing slide. The baseplate is attached to the bottom end of the housing and has at least one ejecting opening. The storage containers are adapted for receiving and storing solid forms of medications. Each storage container has a bottom opening. A dosing slide is movably mounted between the storage containers and the baseplate and has receiving openings arranged in the dosing slide so that each of the receiving openings can be positioned under a bottom opening of a storage container and above an ejecting opening.
Abstract: Arginine mimetic peptides according to Formula I of this application have a stimulating effect on bone formation and are useful for the treatment of bone metabolic disorders.
Abstract: The invention concerns storage-stable lyophilized pharmaceutical preparations of biomolecules wherein the biomolecules are selected from the group comprising proteins, peptides, nucleic acids and carbohydrates and additionally contain one or several basic D or L-amino acids in addition to one or several aminodicarboxylic acids, hydroxycarboxylic acids or dicarboxylic acids or physiologically compatible salts thereof. The auxiliary substances are present in the lyophilisate in a completely or partially amorphous form.
Type:
Application
Filed:
January 16, 2002
Publication date:
August 1, 2002
Applicant:
Roche Diagnostics GmbH
Inventors:
Wolfgang Rodel, Markus Mattern, Gerhard Winter
Abstract: Method for monitoring insulin medication in which blood sugar values are determined before and after a meal. The difference between these measured values is plotted against a quotient calculated from the bread units ingested during the meal and the insulin units used to compensate for these bread units. Displaying many such points on a graph provides criteria for improving the insulin medication.
Type:
Grant
Filed:
February 28, 2001
Date of Patent:
July 30, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Karl Werner, Peter Blasberg, Wilfried Muller
Abstract: The invention concerns a device for cleaning pipette needles or stirrers, the device comprising a trough which holds cleaning fluid and whose lower region has a fluid duct for filling and/or emptying purposes and whose upper region has at least one feed pipe which leads into at least one nozzle directed into the trough interior. Advantageously, the device has a cylindrical trough and an insert with nozzles which is screwed into the trough. The invention further concerns a method of cleaning pipette needles or stirrers, the material to be washed being introduced into the trough interior and sprayed with a washing fluid. The device can also be used to flush the interior of a pipette needle.
Type:
Grant
Filed:
December 15, 1998
Date of Patent:
July 23, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Otto Fürst, Thomas Jäck, Peter Weber, Paul Jansen
Abstract: Device for withdrawing Blood for Diagnostic Purposes. A lancet holder (8) for holding a lancet (7) and a lancet drive (12) having a loadable elastic drive spring (15) are provided within an elongated housing (2). The relaxing motion of the drive spring (15) is converted into a puncturing motion, after release of a locking device, to move the lancet (7), held by the lancet holder (8), at high speed in the puncturing direction until its tip exists out of an exit opening (5) of the housing (2).
An improved handling and simultaneous minimization of pain is achieved by providing a two-sided rotary/translatory transmission (25) in the housing (2), wherein
a) the input side (24) of the rotary/translatory transmission (25) transforms the motion of a loading button (17), protruding out of the rear end (16) of the housing.
Abstract: The present invention concerns muteins of avidin and streptavidin with a reduced binding affinity for biotin as well as their use as interference elimination reagents in methods for the determination of an analyte e.g. in diagnostic tests such as for example immunoassays and nucleic acid hybridization assays. In addition the invention concerns the use of muteins of avidin and streptavidin as systems capable of regeneration for binding biotin e.g. for the analysis of biotinylated molecules, for examining receptor ligand interactions as well as for the affinity purification of biotinylated molecules.
Type:
Grant
Filed:
August 5, 1999
Date of Patent:
July 9, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Eberhard Kopetzki, Rainer Müller, Richard Engh, Urban Schmitt, Arno Deger, Hans Brandstetter
Abstract: A stabilized reagent for the photometric enzymatic determination of creatine kinase (CK) in biological sample material by forming ATP from creatine phosphate and ADP and detecting the ATP formed, containing an organic or inorganic sulphur compound preferably in a submolar amount relative to the added CK activator. A corresponding reagent in a liquid form is stable at 2 to 8° C. for up to 12 months without significant loss of function.
Abstract: The discriminating capability of hybridization assays is increased by a combination of labelled primers which produce amplificates of one strand of a nucleic acid with a capture probe which is complementary to the same strand of the nucleic acid.
Abstract: Blood lancet for withdrawing blood for diagnostic purposes. It has a housing with an outlet opening for the tip of a lancet, and a lancet drive with a drive rotor driven in a sense of rotation by a drive spring. The drive rotor converts the relaxation movement of the drive spring to a pricking movement, moving the lancet with high speed in pricking direction, until the tip protrudes from the outlet opening. The drive rotor has a pressure surface directed radially outwardly and running around the rotation axis with varying center distance. The pressure surface has a vertex with maximum center distance, and a propelling section, following the vertex against the sense of rotation and having a center distance decreasing against the sense of rotation. The drive spring effects a pressure on the propelling section of the pressure surface, thus driving the drive rotor in sense of rotation, whereas the drive rotor is coupled to the lancet holder.
Abstract: The invention concerns a DNA coding a eukaryotic highly active alkaline phosphatase with a specific activity of more than 3000 U/mg. The invention also concerns a process for the production of a DNA according to the invention, a vector containing the DNA according to the invention and a cell line containing this vector. Furthermore the invention concerns a recombinant highly active alkaline phosphatase with a specific activity of more than 3000 U/mg which is coded by the DNA according to the invention.
Type:
Grant
Filed:
May 5, 1999
Date of Patent:
June 18, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Werner Hoelke, Rainer Muller, Helmut Burtscher, Jose Luis Millan
Abstract: Method for synthesizing or sequencing a nucleic acid molecule in a thermocycling reaction which initially comprises a nucleic acid molecule, a first primer, a second primer, a reaction buffer, a first thermostable enzyme e.g. a DNA polymerase, (optionally) a thermostable pyrophosphatase, deoxynucleotides or derivatives thereof and in case of a sequencing method a dideoxynucleotide or a derivative thereof and which is characterized in that the thermocycling reaction additionally contains a second thermostable enzyme e.g. a DNA polymerase which, in comparison to the said first thermostable enzyme, exhibits a different enzymatic activity as e.g. has a reduced ability to incorporate dideoxynucleotides as well as the use of the said method. At least one polymerase is initially inhibited whereby the inhibiting agent loses inhibitory ability at cycles of the thermocycling reaction.
Abstract: A process for producing erythropoietin which is free of foreign animal proteins except for the proteins of the host cell, wherein DNA coding for EPO is expressed in a eukaryotic host cell and the host cell is cultured in a medium free of natural mammalian proteins. The erythropoietin is chromatographically purified using dye affinity chromatography, chromatography on hydroxyapatite, reversed phase chromatography, and anion exchange chromatography. The resulting preparation contains less than 100 ppm of proteins derived from the host cell, and less than 10 pg of host cell DNA per 83 &mgr;g erythropoietin.
Type:
Grant
Filed:
February 13, 1998
Date of Patent:
June 4, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Josef Burg, Walter Schneider, Alexander Wrba, Werner Fürst, Karl-Heinz Sellinger
Abstract: This invention relates to a test element and a method for determining the ratio of glycated to non-glycated haemoglobin in a sample, for example, in a blood sample that is provided as a fresh sample, a dried sample or a haemolysed sample. The test element can include different zones for receiving the sample, serving as a depot for reagents such as non-immobilized signal-generating molecules or haemolysis reagents, separating reagents from the sample, and detecting heamoglobin. The zones are provided on a porous matrix and in fluid contact with each other. The method uses the test element and determines the ratio of glycated to non-glycated haemoglobin in a sample, by contacting the sample with an excess of signal generating molecules to bind to the glycated haemoglobin. The non-bound signal generating molecules are separated from the sample, and the amount or concentration of haemoglobin and/or glycated haemoglobin bound signal generating molecules are determined.
Abstract: A process for selecting human cells for the production of human proteins by endogenous gene activation allows human proteins to be produced in economically feasible quantities and in a form suitable for producing a pharmaceutical composition. Also disclosed is a process for producing human proteins in a cell line identified in this matter.
Type:
Grant
Filed:
May 30, 2000
Date of Patent:
May 28, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Michael Brandt, Reinhard Franze, Ulrich Pessara
Abstract: The present invention concerns muteins of avidin and streptavidin with a reduced binding affinity for biotin as well as their use as interference elimination reagents in methods for the determination of an analyte e.g. in diagnostic tests such as for example immunoassays and nucleic acid hybridization assays. In addition the invention concerns the use of muteins of avidin and streptavidin as systems capable of regeneration for binding biotin e.g. for the analysis of biotinylated molecules, for examining receptor ligand interactions as well as for the affinity purification of biotinylated molecules.
Type:
Grant
Filed:
August 4, 1999
Date of Patent:
May 21, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Erhard Kopetzki, Rainer Müller, Richard Engh, Urban Schmitt, Arno Deger, Hans Brandstetter